As a new type of foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system and can supply chitosan sourced from multiple well-known original manufacturers.
Possessing R&D capabilities, HiSiaddi has repeatedly collaborated with factories on technological transformation and conducted multiple rounds of field investigations of chitosan manufacturers, accumulating objective and in-depth insights into different brands. We regularly analyze various chitosan manufacturers for customers to help them select matching products. Below is a brand selection service case.
Please contact HiSiaddi customer service for more brand and model comparative analysis.
The buyer is NaturaDerm S.L., a leading mid-to-high-end medical aesthetic and medical skincare enterprise based in Barcelona, Spain, specializing in three premium product lines: post-procedure repair gels, hospital medical dressings, and oral slimming capsules. Its products comply with EU CE certification, Spain’s AEMPS drug administration regulations, and LFGB safety specifications, sold exclusively in private medical aesthetic chains and premium organic drugstore supermarkets across Spain, with stable annual procurement of 9.8 tons of pharmaceutical-grade chitosan divided into three subcategories: low-molecular water-soluble medical aesthetic gel grade, high-molecular film-forming dressing grade, and oral sustained-release capsule grade. It previously sourced high-end chitosan raw materials from France for a long time and initiated domestic Chinese procurement amid rising European raw material prices and extended delivery cycles.
The customer independently contacted five leading domestic chitosan manufacturers (the five mainstream domestic medical-grade chitosan brands): Zhejiang Golden-Shell, Qingdao Hainuo, Weifang Yingke, Guangdong Huada, and Jiangsu Jingguan. All sales teams operated compliantly without maliciously slandering competitors, yet each only promoted their full product lines and avoided objective explanations of competitors’ advantages, applicable scenarios, and parameter weaknesses, claiming all their models fully matched the customer’s three formulation systems. Lacking industry knowledge of China’s chitosan sector, the customer could not distinguish process and parameter differences between brands. After self-funding 12 batches of test samples from five manufacturers with testing expenses exceeding EUR 4,200, mass production after sample testing triggered three consecutive issues: gel precipitation and stratification, cracked dressing films, and excessive capsule dissolution rates, stalling R&D progress for 38 days and delaying finalization of long-term supply brands. Upon industry recommendation, the customer fully entrusted HiSiaddi to conduct horizontal cross-brand evaluation and precision brand selection services.
Mandatory core selection parameters specified by the customer:
1. Medical aesthetic gel dedicated: low-molecular modified chitosan, deacetylation degree 93%–95%, molecular weight 18,000–25,000 Da, cold water soluble, quaternary ammonium substitution degree 36%–39%, compatible with repair gel compound systems;
2. Medical dressings: high-molecular chitosan, molecular weight 720,000–780,000 Da, deacetylation degree ≥90%, strong film-forming ductility, endotoxin <0.15 EU/mg;
3. Oral capsules: narrow-distribution medium-molecular chitosan, molecular weight 30,000–38,000 Da, deacetylation degree 94%±1%, controllable gastric juice sustained release, compliant with EP Pharmacopoeia raw material standards.
Drawing on chitosan industrial chain resources, HiSiaddi independently accessed factory quality inspection reports, third-party CNAS actual test data, and EU export batch records. Setting aside promotional claims from each manufacturer, it neutrally analyzed the five brands across four dimensions: production processes, strengths & weaknesses, mainstream models, and applicable scenarios, compiling a Chinese-English bilingual parameter comparison table for customer delivery.
Core Strengths: Joint laboratory collaboration with Zhejiang University, industry-leading mature modification processes for quaternary ammonium and carboxymethyl modification, stable deacetylation degree ranking top in the industry, full medical-grade series internal control aligned with EP/USP Pharmacopoeia, over 20 years of exports to European and American pharmaceutical enterprises; Product Weaknesses: Average high-molecular weight retention processes for ultra-high molecular weight chitosan above 700,000 Da, with large molecular weight fluctuations across mass production batches; raw material unit prices are 8%–12% higher than the other four brands at the same quality level; Mainstream Available Models: ① JK-LM095: low-molecular modified chitosan (deacetylation degree 95%, 18,000–26,000 Da, gel dedicated); ② JK-MM094: medium-molecular oral-grade (32,000 Da, capsule sustained-release raw material); ③ JK-HM090: general high-molecular dressing chitosan (550,000–680,000 Da).
Core Strengths: Self-owned deep-sea shrimp shell raw material bases, mature low-temperature deacetylation processes for high-molecular chitosan, industry-leading stable mass production of 700,000–800,000 Da high-viscosity high-molecular products, excellent endotoxin control, outstanding cost performance for dressing-grade products; Product Weaknesses: Limited production capacity for refined quaternary ammonium modification production lines, extended customized lead times for modified grades, low precision of narrow molecular weight grading for low-molecular products compared to Golden-Shell; Mainstream Available Models: ① HN-H75: high-molecular dressing dedicated (750,000 Da, deacetylation degree 90.5%); ② HN-M35: general medium-molecular oral chitosan; ③ HN-L general low-molecular grade (broad molecular weight span, unsuitable for high-precision high-end medical aesthetic formulations).
Core Strengths: Mature biodegradation enzymatic hydrolysis processes, extremely low molecular weight dispersion coefficient for low-molecular chitosan, precise narrow grading, excellent water solubility, outstanding advantages for medical aesthetic small-molecule raw materials; Product Weaknesses: Small-scale mass production of high-molecular products, ultra-high molecular weight models mostly produced in small-batch pilot lots with unstable mass supply capacity; Mainstream Models: YK-L22 (precision low-molecular modified chitosan 19,000–24,000 Da), YK-M general oral grade.
Core Strengths: Specializes in composite modification of chitosan and hyaluronic acid, mainly supplying cosmetic and medical aesthetic semi-finished raw materials; Product Weaknesses: Internal control indicators for pharmaceutical oral-grade and high-purity dressing-grade products fail to meet EU Pharmacopoeia standards with high endotoxin levels, incompatible with the customer’s capsule and sterile dressing access requirements.
Core Strengths: Large mass production scale and low unit prices; Product Weaknesses: No GMP medical production lines, volatile deacetylation degrees, loose control of heavy metal and protein impurities, only suitable for low-end food and agricultural applications, mismatched with the customer’s mid-to-high-end pharmaceutical and medical aesthetic access standards.
Combined with the customer’s three high-end application scenarios (medical aesthetic gel, sterile dressings, oral capsules) and stringent EU compliance procurement requirements, Huada and Jingguan were eliminated for failing to meet EU Pharmacopoeia indicator standards, while Yingke was ruled out for unstable mass production of high-molecular products. From the remaining three brands, two mid-to-high-end leading manufacturers – Zhejiang Golden-Shell and Qingdao Hainuo – were selected, with three fixed models precisely finalized to fully cover all three raw material requirements.
1. Model JK-LM095 (modified low-molecular chitosan): stable quaternary ammonium substitution degree of 37%–38.5%, deacetylation degree 94.8%, molecular weight approximately 21,000 Da, fully soluble in cold water, perfectly compatible with the customer’s Spanish post-procedure repair gel formulation, resolving previous gel stratification and precipitation issues;
2. Model JK-MM094 (medium-molecular oral dedicated chitosan): molecular weight 34,000 Da, deacetylation degree 94.2%, narrow molecular weight distribution, with capsule gastric juice disintegration and drug dissolution fully compliant with Spanish Pharmacopoeia standards.
1. Model HN-H75 (high-molecular dressing chitosan): actual measured molecular weight 752,000 Da, deacetylation degree 90.3%, endotoxin 0.12 EU/mg, flexible film formation resistant to cracking, fully meeting mass production standards for sterile wound dressings.
Summary of Brand Selection Logic: Golden-Shell boasts top-tier modification and oral-grade production processes with complete compliance documents for EU drug administration filing; Hainuo delivers industry-leading stability and cost performance for high-molecular dressing raw materials. Complementary strengths of the two manufacturers fully cover the customer’s three product raw material demands, avoiding risks of single-source raw material supply by avoiding full procurement from one brand.
1. Small Trial Sample Phase: HiSiaddi coordinated both factories to ship 5kg sterile samples of each selected model, accompanied by EP English COA quality inspection reports, raw material traceability certificates, GMP production qualifications, and non-irradiation statements. The customer’s Spanish R&D laboratory conducted full compatibility, accelerated stability, and biocompatibility testing, with all three samples passing all indicators at one time without abnormalities.
2. Small-Batch Trial Order: The customer first trialed a purchase of 1.2 tons (0.4 tons gel raw material, 0.4 tons capsule raw material, 0.4 tons dressing raw material), with three production lines operating continuously for 72 hours during trial production, and all finished products passing random inspections by Spain’s AEMPS drug administration.
3. Annual Framework Order Implementation: After successful trial production, an annual framework procurement order of 9.8 tons was finalized: 5.6 tons total from Golden-Shell’s two models (3.1 tons gel raw material + 2.5 tons capsule raw material), 4.2 tons Hainuo dressing-grade raw material, shipped in 11 evenly distributed monthly batches. HiSiaddi coordinated unified export customs clearance and Spanish FORM A certificate of origin processing, enabling the customer to reduce import tariffs.
① Terminated blind sample testing losses, saving over EUR 4,000 in invalid pre-sample and third-party testing costs. Domestic raw material procurement reduced comprehensive costs by 22.8% compared to original French imported raw materials, enabling timely full-channel launch of three new products in Spain with a 28% increase in clinical channel revenue in the first year. ② Established internal Chinese chitosan procurement standards via HiSiaddi’s neutral selection services. In the following year, all chitosan raw material procurement for its Portuguese subsidiaries was fully entrusted to HiSiaddi for brand selection and purchasing, expanding annual procurement volume to 13.5 tons.
Golden-Shell and Hainuo secured stable bulk orders via this project, opening up Spain’s high-end medical aesthetic raw material supply chain. Later, relying on customer referrals, they obtained designated supply qualifications for three mid-to-high-end European pharmaceutical and cosmetic enterprises in Portugal and Greece, achieving significant export growth of high-end medical-grade chitosan.
Moving beyond the traditional model of intermediary purchasing, HiSiaddi acts as a neutral third-party raw material evaluation service provider, breaking the industry pain point that domestic manufacturers only promote their own products and avoid disclosing competitors’ advantages. Leveraging a full-industry brand database and actual test data, it eliminates information barriers for overseas mid-to-high-end customers and precisely matches suitable models, forming a standardized neutral brand selection service model for chitosan supply to high-end European and American pharmaceutical enterprises.
Domestic leading chitosan manufacturers feature distinct differentiated product lines, with respective strengths in modification, high-molecular weight, and low-molecular weight subdivided sectors. However, driven by sales performance assessment, manufacturers generally prioritize promoting their own products and refuse to objectively disclose competitors’ advantages. Lacking understanding of segmented differences among domestic brands, mid-to-high-end overseas pharmaceutical enterprises easily encounter blind sample testing, selection errors, and formulation scrapping. Drawing on full industrial chain resources and raw material testing capabilities, HiSiaddi neutrally cross-analyzes strengths and weaknesses of multiple brands, and precisely screens brands and models based on customers’ terminal formulation and import regulatory requirements. It not only reduces customer trial-and-error costs but also realizes accurate matching between supply and demand, serving as a typical case of foreign trade facilitating high-end raw material transactions via professional brand selection services.
Please contact HiSiaddi customer service for more brand and model comparative analysis.
+86-13120989737 
info@hisiaddi.com 
English
